Benzinga · Aug 17, 2026
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
NASDAQ · CRDL
Healthcare · Drug Manufacturers - Specialty & Generic
$1.86
Down-$0.03 (-1.33%)
Updated Aug 22, 2026, 5:48 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CRDL closed at $1.86 after 21 trading sessions, up 57.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.93 | $1.9319 | $1.855 | $1.86 | 753.35K |
| Aug 20, 2026 | $1.96 | $1.995 | $1.83 | $1.885 | 1.53M |
| Aug 19, 2026 | $1.92 | $1.965 | $1.86 | $1.96 | 1.75M |
| Aug 18, 2026 | $1.82 | $1.90 | $1.735 | $1.895 | 1.6M |
| Aug 17, 2026 | $1.73 | $1.94 | $1.73 | $1.80 | 2.33M |
| Aug 14, 2026 | $1.73 | $1.82 | $1.65 | $1.80 | 1.73M |
| Aug 13, 2026 | $1.49 | $1.77 | $1.49 | $1.71 | 2.14M |
| Aug 12, 2026 | $1.51 | $1.52 | $1.43 | $1.52 | 790.97K |
| Aug 11, 2026 | $1.49 | $1.53 | $1.445 | $1.50 | 776.24K |
| Aug 10, 2026 | $1.44 | $1.50 | $1.38 | $1.47 | 1.52M |
| Aug 7, 2026 | $1.36 | $1.425 | $1.35 | $1.42 | 327.19K |
| Aug 6, 2026 | $1.32 | $1.385 | $1.315 | $1.36 | 790.16K |
| Aug 5, 2026 | $1.36 | $1.38 | $1.31 | $1.34 | 1.07M |
| Aug 4, 2026 | $1.30 | $1.37 | $1.275 | $1.36 | 1.54M |
| Aug 3, 2026 | $1.29 | $1.33 | $1.21 | $1.31 | 778.74K |
| Jul 31, 2026 | $1.23 | $1.29 | $1.20 | $1.27 | 1.15M |
| Jul 30, 2026 | $1.16 | $1.24 | $1.14 | $1.21 | 897.98K |
| Jul 29, 2026 | $1.20 | $1.21 | $1.145 | $1.15 | 916.11K |
| Jul 28, 2026 | $1.16 | $1.225 | $1.1106 | $1.20 | 992.45K |
| Jul 27, 2026 | $1.20 | $1.21 | $1.15 | $1.155 | 552.38K |
| Jul 24, 2026 | $1.23 | $1.25 | $1.15 | $1.18 | 680.4K |
The latest Smart Investors Daily articles mentioning CRDL.


The latest Smart Investors Daily articles mentioning CRDL.
No results
No recent SID articles mention CRDL.
CRDL research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
1 matching article.
Benzinga · Aug 17, 2026
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.